Abstract
Objective To describe the total birth prevalence of neural tube defects (NTDs) in Scotland 2000-2021.
Design National, population-based study.
Setting Scotland, UK.
Participants Babies with an NTD and pregnancy outcome of live birth, stillbirth (≥20 weeks gestation), or termination of pregnancy (any gestation), as recorded in the Scottish Linked Congenital Condition Dataset.
Exposures Year, maternal age group, maternal area-level deprivation quintile.
Main outcome measures Total birth prevalence of all NTDs and, separately, anencephaly and spina bifida (per 10,000 total births). The association between exposures and outcomes was investigated using Poisson regression.
Results In Scotland 2000-2021, there were 1,178 babies with a recorded NTD (436 anencephaly, 577 spina bifida) and 1,203,491 total births. Total birth prevalence of NTDs was 9.8 [95% CI 9.2, 10.4] per 10,000 total births. Prevalence was lower among babies to mothers aged 30-39 years (compared to younger or older) and those from less (compared to more) deprived areas. There was no evidence of change over the study period in prevalence of NTDs (prevalence rate ratio [PRR] 1.01 [95% CI 0.997, 1.02] p=0.16), or spina bifida (PRR 0.99 [95% CI 0.98, 1.01] p=0.35). The prevalence of anencephaly showed no change 2000-2012, then increased 2013-2021 (PRR 1.12 [95% CI 1.06, 1.19] p<0.001).
Conclusions Observed trends in anencephaly likely reflect increasing detection in early pregnancy. Current strategies are failing to equitably reduce NTDs in Scotland. Monitoring of future trends is needed to assess the impact of mandatory folic acid fortification.
What is already known on this topic
- Recommendations for voluntary fortification of some foods, and for pre-conception daily supplements of folic acid, have been in place since the 1980s and 1990s respectively to support prevention of neural tube defects (NTDs).
- Most women do not take folic acid supplements before conception, and uptake is particularly low in younger mothers and those from poorer socioeconomic backgrounds.
- Legislation to mandate the fortification of non-wholemeal wheat flour with folic acid was introduced in November 2024. This provides an opportunity to improve the equitable prevention of NTDs.
What this study adds
- There is no evidence that the total birth prevalence of NTDs in Scotland changed 2000-2021. Prevalence was lowest among mothers in the 30-39 year age group, and those from less deprived areas.
- There is no evidence that the total birth prevalence of spina bifida in Scotland changed 2000-2021, however the prevalence of anencephaly increased 2013-2021, likely reflecting increasing early antenatal detection of this condition through ultrasound scans.
How this study might affect research, practice, or policy
- This study provides baseline information for the period before the introduction of mandatory fortification. It will be used to support the evaluation of mandatory fortification, and hence guide future policy development.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://publichealthscotland.scot/publications/trends-in-neural-tube-defects-protocol/
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involved the secondary analysis of routinely collected data and approval by an ethics committee was not required as informed by the NHS Health Research Authority and Public Health Scotland research risk assessment checklists. A Data Protection Impact Assessment for this study was approved by the PHS Data Protection Officer (DP22230101).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
Subject to governance approvals, researchers can access pseudonymised extracts of datasets used in this study through the Scottish NHS safe haven facility supported by Public Health Scotland. Interested researchers should submit an initial enquiry form to Research Data Scotland (https://www.researchdata.scot/accessing-data/).
